GSK-3 as potential target for therapeutic intervention in cancer
- PMID: 24931005
- PMCID: PMC4102778
- DOI: 10.18632/oncotarget.2037
GSK-3 as potential target for therapeutic intervention in cancer
Abstract
The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified and studied in the regulation of glycogen synthesis. GSK-3 functions in a wide range of cellular processes. Aberrant activity of GSK-3 has been implicated in many human pathologies including: bipolar depression, Alzheimer's disease, Parkinson's disease, cancer, non-insulin-dependent diabetes mellitus (NIDDM) and others. In some cases, suppression of GSK-3 activity by phosphorylation by Akt and other kinases has been associated with cancer progression. In these cases, GSK-3 has tumor suppressor functions. In other cases, GSK-3 has been associated with tumor progression by stabilizing components of the beta-catenin complex. In these situations, GSK-3 has oncogenic properties. While many inhibitors to GSK-3 have been developed, their use remains controversial because of the ambiguous role of GSK-3 in cancer development. In this review, we will focus on the diverse roles that GSK-3 plays in various human cancers, in particular in solid tumors. Recently, GSK-3 has also been implicated in the generation of cancer stem cells in various cell types. We will also discuss how this pivotal kinase interacts with multiple signaling pathways such as: PI3K/PTEN/Akt/mTORC1, Ras/Raf/MEK/ERK, Wnt/beta-catenin, Hedgehog, Notch and others.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4102778/bin/oncotarget-05-2881-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4102778/bin/oncotarget-05-2881-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4102778/bin/oncotarget-05-2881-g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4102778/bin/oncotarget-05-2881-g004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4102778/bin/oncotarget-05-2881-g005.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4102778/bin/oncotarget-05-2881-g006.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4102778/bin/oncotarget-05-2881-g007.gif)
Similar articles
-
The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.Biomed Pharmacother. 2020 Aug;128:110249. doi: 10.1016/j.biopha.2020.110249. Epub 2020 May 26. Biomed Pharmacother. 2020. PMID: 32470749
-
Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer.Semin Cancer Biol. 2019 Jun;56:25-36. doi: 10.1016/j.semcancer.2017.12.010. Epub 2018 Jan 5. Semin Cancer Biol. 2019. PMID: 29309927 Review.
-
Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer.Biochim Biophys Acta. 2016 Dec;1863(12):2942-2976. doi: 10.1016/j.bbamcr.2016.09.004. Epub 2016 Sep 6. Biochim Biophys Acta. 2016. PMID: 27612668 Review.
-
Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.Leukemia. 2014 Jan;28(1):15-33. doi: 10.1038/leu.2013.184. Epub 2013 Jun 19. Leukemia. 2014. PMID: 23778311 Free PMC article. Review.
-
Glycogen synthase kinase 3: a key regulator of cellular fate.Cell Mol Life Sci. 2007 Aug;64(15):1930-44. doi: 10.1007/s00018-007-7045-7. Cell Mol Life Sci. 2007. PMID: 17530463 Free PMC article. Review.
Cited by
-
Mitochondrial translation failure represses cholesterol gene expression via Pyk2-Gsk3β-Srebp2 axis.Life Sci Alliance. 2024 May 8;7(7):e202302423. doi: 10.26508/lsa.202302423. Print 2024 Jul. Life Sci Alliance. 2024. PMID: 38719751 Free PMC article.
-
Germ cell-specific gene 2 accelerates cell cycle in epithelial ovarian cancer by inhibiting GSK3α-p27 cascade.J Mol Histol. 2024 Jun;55(3):241-251. doi: 10.1007/s10735-024-10185-6. Epub 2024 Apr 13. J Mol Histol. 2024. PMID: 38613588 Free PMC article.
-
Antineoplastic effect of compounds C14 and P8 on TNBC and radioresistant TNBC cells by stabilizing the K-Ras4BG13D/PDE6δ complex.Front Oncol. 2024 Mar 20;14:1341766. doi: 10.3389/fonc.2024.1341766. eCollection 2024. Front Oncol. 2024. PMID: 38571493 Free PMC article.
-
Contractile and Genetic Characterization of Cardiac Constructs Engineered from Human Induced Pluripotent Stem Cells: Modeling of Tuberous Sclerosis Complex and the Effects of Rapamycin.Bioengineering (Basel). 2024 Feb 28;11(3):234. doi: 10.3390/bioengineering11030234. Bioengineering (Basel). 2024. PMID: 38534508 Free PMC article.
-
Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull's eye for targeted therapy?Front Immunol. 2024 Mar 5;15:1340726. doi: 10.3389/fimmu.2024.1340726. eCollection 2024. Front Immunol. 2024. PMID: 38504984 Free PMC article. Review.
References
-
- Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem. 1980;107:519–527. - PubMed
-
- Gao C, Holscher C, Liu Y, Li L. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Reviews in the Neurosciences. 2012;23:1–11. - PubMed
-
- Forlenza OV, de Paula VJ, Machado-Vieira R, Diniz BS, Gattaz WF. Does lithium prevent Alzheimer's disease? Drugs & Aging. 2012;29:335–342. - PubMed
-
- Amar S, Belmaker RH, Agam G. The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases. Current Pharmaceutical Design. 2011;17:2264–2277. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous